Supriya Lifescience Limited IPO GMP, Allotment Date, Status, Price

The Mumbai-primarily based totally lively prescription drugs ingredients (APIs) manufacturer, Supriya Lifescience, is about to open its Supriya Lifescience Limited IPO GMP on December 16. The company produces 38 APIs focused on different therapeutic segments such as antihistamines, pain relievers, anesthetics, vitamins, anti-asthmatic and anti-allergic drugs. Supriya Lifescience merchandise had been exported to 86 nations and 1,296 clients in FY21. The corporation has API enterprise in Europe, Latin America, Asia, and North America. He is looking to raise 700 crores through the IPO, which consists of a new issue of 200 crore and a sell offer of ₹ 500 crore.

Supriya Lifescience Limited IPO GMP

  • Supriya Lifescience manufactures Active Pharmaceutical Ingredients (APIs). It produces 38 ingredients focused on therapeutic segments such as pain relievers, anesthetics, antiallergics,
  • It seeks to raise 700 crores through the IPO which consists of a new issue of ₹ 200 crore and a sell offer of ₹ 500
  • The company’s IPO will open and close on December It has a price range of 265-274 per share.
  • Individual investors can bid on a minimum of 54 shares with a value of 14,796 per

Objects of the Issue

  • Financing of the Company’s investment expenditure requirements;
  • Repayment and/or prepayment, in whole or in part, of certain loans used by the Company and
  • General commercial purposes

Supriya Lifescience Limited IPO

Supriya Lifescience Limited IPO Details

Objects of the issue
  • Funding New CAPEX requirement of the company
  • Repayment/Prepayment of current Borrowing of the company.
  • General corporate purposes.
Issue Size
  • Total issue size -Rs. 700 Cr.
  • Offer for Sale – Rs. 500 Cr.
  • Fresh Issue – Rs. 200 Cr.
Face value Rs.2.00 Per Equity Share
Issue Price Rs. 265 – Rs.274
Bid Lot 54 shares
Listing at  BSE, NSE
Issue Opens: 16thDec, 2022 – 20th Dec, 2022
QIB 75% of Net Issue Offer
Retail 10% of Net Issue Offer
NIB 15% of Net Issue Offer

Important Dates Associated With The IPO

Price Band ₹265 To ₹274
IPO Open Date December 16
IPO Close Date December 20
Allotment Date December 23
Initiation Of Refunds December 24
Credit Of Shares To Demat Account December 27
IPO Listing Date December 28
Minimum Lot 54

The net proceeds of the new issue will be used for capital expenditures, debt repayment, and general business purposes.

Supriya Lifescience IPO Provisional Timetable

The Supriya Lifescience IPO open date is Dec 16, 2022, and the near date is Dec 20, 2022. The problem might also additionally list on Dec 28, 2022.

IPO Open Date Dec 16, 2022
IPO Close Date Dec 20, 2022
Basis of Allotment Date Dec 23, 2022
Initiation of Refunds Dec 24, 2022
Credit of Shares to Demat Account Dec 27, 2022
IPO Listing Date Dec 28, 2022

Supriya Lifescience IPO Date And Price Band

 IPO Open:  16 December 2022
 IPO Close:  20 December 2021
 IPO Size:  Approx ₹700 Crores
 Fresh Issue:  Approx ₹200 Crores
 Offer for Sale:  Approx ₹500 Crores
 Face Value:  ₹2 Per Equity Share
 Price Band:  ₹265 to ₹274 Per Share
 Listing on:  BSE & NSE
 Retail Quota:  10%
 QIB Quota:  75%
 NII Quota:  15%
 Discount:  ₹- for Retail Investors

Company’s Address

Supriya Lifescience Limited

207/208, Udyog Bhavan, Sonawala Road,

Goregaon–East, Mumbai – 400063,

Maharashtra, India

Tel: +91-22-40332727

Contact Person: Shweta Shivdhari Singh

Company Secretary and Compliance Officer

Tel: +91-22-40332727

E-mail: [email protected]


Corporate Identity Number: U51900MH2008PLC180452OUR

Supriya Lifescience Company Financial Report (Cr)

Year Revenue Expense P&L
2021 ₹25,993.50 ₹23,694.00 ₹1,520.73
2020 ₹21,762.53 ₹21,377.81 ₹230.24
2019 ₹21,591.22 ₹21,037.06 ₹851.33

Supriya Lifescience Limited IPO Risk Factors

  • The company generates a significant portion of its revenue from a few players, so a loss of customers can have a significant impact on the company’s revenue.
  • The company operates in a highly regulated industry and must adhere to the safety and manufacturing regulations of various agencies, so any deficiency in manufacturing standards may preclude their

Supriya Lifescience Limited IPO Outlook

Supriya Lifesciences Limited is the largest exporter of chlorpheniramine maleate, Ketamine hydrochloride, and India salbutamol sulfate, provides their product in India and Global Pharma Company, about 70% of revenues come from the export market in which they provide

Supriya’s facility is certified by all of the world’s top pharmaceutical agencies and has strong RandD capability and regularly enters niche products.

The company has shown strong financial performance over the past three years and this trend is expected to continue due to China’s plus one policy and the government’s initiative to become self-sufficient in the API space.

At the highest price bracket of 274,274, the company will trade at a P / E of 17.81x after the issuance of FY21E, which is in line with other API companies, so we recommend that you SIGN UP for this Supriya Lifescience Limited IPO GMP.

Official Website Click Here
DMER Homepage Click Here

Leave a Comment